Prabhudas Lilladher Maintains 'Accumulate' Ratings for Zydus Lifesciences and Lupin
Prabhudas Lilladher's research reports on Zydus Lifesciences and Lupin highlight largely in-line Q2 earnings with expectations. Zydus is managing revenue transitions amid declining gRevlimid sales and plans multiple high-value product launches by FY27-28, aiming for US sales growth. Lupin faces margin pressures and increased competition in key products, with some pipeline prospects to offset declines. Both companies have revised EPS estimates downward slightly but maintain 'Accumulate' ratings with target prices of Rs 1,200 for Zydus and Rs 2,250 for Lupin.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 29/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–65/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 6 Nov, 06:29 am. Other outlets followed.